St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases
NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
Genetic change increased bird flu severity during U.S. spread
Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
SWI/SNF complexes “bookmark” cell identity during division
Read about how Scientists at St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
Epigenetic landscape modulates pioneer transcription factor binding
St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
Capturing transporter structure paves the way for drug development
Learn how St. Jude scientists captured six new structures of the Spns2 transporter, providing insights to aid therapeutic design for cancer and other diseases.
St. Jude scientist M. Madan Babu elected to the Royal Society of London
Director of the St. Jude Center of Excellence for Data-Driven Discovery named a fellow of the 360-year-old British scientific organization.
St. Jude tool gets more out of multi-omics data
NetBID2 finds hidden drivers by extracting more from multi-omics data. Learn how the computational tool can find druggable targets in cancer and other diseases.
Study shines light on impact of environment on neurocognitive outcomes
Find how the neighborhood economic hardship index predicts baseline and long-term outcomes in pediatric brain tumor patients treated with radiation therapy.
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma
Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
Prime editing shows proof of concept for treating sickle cell disease
Genomic prime editing, a new DNA-changing technology, fixed sickle cell disease mutations in patient cells. Learn how it could lead to cure for genetic anemias.
Explore more research news
More Research News
2022 Scientific Report
The Scientific Report, Translating Science into Survival, describes key breakthroughs made by St. Jude investigators.
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.